Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (NASDAQ: BCAX), reported a paired option exercise and share sale on March 3, 2026. On that date, Cohlhepp sold 17,392 shares of common stock for approximately $315,892, at a weighted average price of $18.1631, with individual trade prices ranging from $18.00 to $18.32.
Simultaneously, Cohlhepp exercised stock options to acquire 12,892 shares at an exercise price of $3.7898 per share, representing a total exercise cost of $48,858. Both the option exercise and the subsequent sales were conducted under a pre-arranged Rule 10b5-1 trading plan that Cohlhepp adopted on February 12, 2025.
Following these transactions, Cohlhepp directly holds 205,141 shares of Bicara Therapeutics common stock.
Market context and recent performance
The stock was trading near its 52-week high of $19.71 at the time of the sale, a material increase from its 52-week low of $7.80. Over the prior six months, BCAX had produced a 53% return. InvestingPro analysis included in company commentary indicates that BCAX currently appears overvalued relative to its Fair Value.
Company capital activity
Bicara Therapeutics recently completed a substantial equity offering, generating roughly $172.5 million in gross proceeds. The financing included the sale of 8,581,250 shares of common stock and pre-funded warrants to purchase 2,200,000 shares. The common stock in that offering was priced at $16.00 per share. The transaction also incorporated 1,406,250 shares sold as part of the underwriters fully exercised option.
Separately, the company had earlier announced the pricing of a $150 million stock offering that included a 30-day option for underwriters to purchase additional shares.
Analyst note
Citizens has reaffirmed its Market Outperform rating for Bicara Therapeutics, maintaining a price target of $31.00. The firm cited a discounted earnings per share and revenue multiple analysis as the basis for the rating and noted Bicaras presentation of long-term follow-up data at the 2026 MHNCS conference.
What the filings show
- Cohlhepp sold 17,392 shares on March 3, 2026, for approximately $315,892 at a weighted average price of $18.1631, range $18.00 to $18.32.
- On the same day he exercised 12,892 options at $3.7898 per share for a total of $48,858.
- Transactions were executed under a Rule 10b5-1 plan adopted February 12, 2025.
- Cohlhepp now holds 205,141 shares directly.
- Bicara completed a $172.5 million gross proceeds offering comprising 8,581,250 common shares and 2,200,000 pre-funded warrants at $16.00 per common share, which included 1,406,250 shares from the underwriters option.
- An earlier $150 million offering had been priced with a 30-day option for underwriters to buy additional shares.
- Citizens reaffirmed a Market Outperform rating with a $31.00 price target and referenced the companys 2026 MHNCS conference data.
Observations
The filings document a routine executive exercise and partial divestment conducted under a pre-established trading plan, occurring while the stock traded near its 52-week peak and after a recent large equity raise. Public commentary referenced in filings points to differing views on valuation, with InvestingPro indicating that BCAX appears overvalued versus Fair Value, and Citizens maintaining a positive outlook through its Market Outperform rating and $31.00 target based on valuation multiples and conference data presentation.